The debate over GLP-1 weight-loss drugs in India has intensified after drugmakers quietly trimmed sales expectations by 25-30% as adoption remains slower than anticipated. According to recent reports, the excitement around generic GLP-1 drugs appears to be cooling faster than expected, with the biggest challenge being patient retention. While generic GLP-1 treatments are now priced between ₹1,000 and ₹2,500 per month, making them more accessible than before, staying committed to long-term treatment remains a significant concern for manufacturers. As reported by The Economic Times, Zerodha Co-founder Nithin Kamath described India as "a weird market" and suggested that Indian doctors may be more conservative in prescribing newer medicines than their Western counterparts. The availability of oral GLP-1 pills could significantly alter the adoption curve by removing one of the biggest barriers - the need for regular injections.
The debate over GLP-1 weight-loss drugs in India has intensified after Biocon Executive Chairperson Kiran Mazumdar-Shaw cautioned against their widespread use among healthy individuals. According to reports from The Economic Times, Mazumdar-Shaw responded to Zerodha Co-founder Nithin Kamath's observations on weaker-than-expected demand for generic versions of the medicines. Her comments came in response to Kamath's post on X platform questioning why demand for generic GLP-1 drugs has failed to take off despite becoming significantly more affordable. As reported by The Economic Times, Mazumdar-Shaw emphasized that GLP-1 drugs should not be the first option for people who are neither diabetic nor clinically obese. She stated that for those who are not diabetic or clinically obese, diet and exercise should be first option. In her latest comments, she noted that India is a weird market and that despite rising obesity rates, she would have expected generic GLP-1 sales to explode once patents expired. She also warned that GLP-1 therapies alter metabolic function and involve neurological signalling, raising questions about their long-term impact.
According to The Economic Times, Zerodha's Nithin Kamath identified several friction points that are discouraging GLP-1 adoption in India. He noted that India's conservative prescribing culture and hesitation around self-injectable treatments are significant barriers. The need for weekly injections and the possibility of regaining weight after stopping the medication may be particularly discouraging to users. Kamath explained that GLP-1s are injectables, and you have to keep taking them. If you stop, you gain back the lost weight. He suggested that convincing people to stay on a weekly injection indefinitely may be difficult, stating it seems like asking someone to stay on a weekly injection indefinitely is a much harder sell. Kamath also raised the important question: could GLP-1 pills significantly improve adoption in India? Despite obesity rates increasing and research showing benefits beyond weight loss, including cardiovascular, metabolic and liver health, stronger demand was expected but retention appears to be the main hurdle. As reported by The Economic Times, Kamath believes affordability is no longer the biggest obstacle - instead, retention is proving to be the real challenge.
According to Mazumdar-Shaw's comments reported by The Economic Times, there are significant gaps in long-term safety data for chronic GLP-1 use. She noted that there is not much long-term data on chronic use of GLP-1s, which represents a key concern for widespread adoption among healthy populations. This lack of comprehensive long-term safety data has become a central point in the ongoing debate about the appropriate use of these weight-loss medications. As reported by The Economic Times, Mazumdar-Shaw warned that GLP-1 drugs alter metabolic function and neurological signalling, and that long-term side effects remain unclear due to limited long-duration data on chronic use. She further highlighted that scientific understanding of prolonged use is still evolving, adding to the concerns about long-term safety implications. The emerging evidence suggests benefits beyond weight loss, including improvements in cardiovascular, metabolic and liver health, but these advantages may not be sufficient to overcome safety concerns among healthcare professionals.
The debate around GLP-1 adoption in India now extends beyond pricing and availability to encompass questions around long-term safety, patient retention and behavioural barriers. According to The Economic Times, Zerodha's Nithin Kamath has observed that generic GLP-1 demand in India is weaker than expected despite the medicines becoming significantly more affordable. This market reality has prompted questions about the effectiveness of price reductions in driving adoption among Indian consumers seeking weight-loss solutions. The weaker-than-anticipated demand suggests that cost considerations alone may not be sufficient to overcome other barriers to adoption, with patient retention emerging as the critical challenge for mainstream adoption. Kamath noted that many users regain weight after discontinuing treatment, which may be particularly discouraging to potential users. The availability of oral GLP-1 pills could significantly improve adoption by removing the need for regular injections, but the debate continues about whether these medications should become the default choice for weight management among healthy individuals.
